deutivacaftor
Small moleculeapproved
Approved
Dec 20, 2024
Clinical trial activity
9 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
5
Phase 3
5
Phase 4
0
Earliest trial started Sep 14, 2021 (NCT05033080)
Timeline
Indications
Approved for
Mechanism of action
Cystic fibrosis transmembrane conductance regulator activator
CFTR modulator
Combination products
alyftrek
with tezacaftor, vanzacaftor
Also known as vanzacaftor, tezacaftor, and deutivacaftor
Approval history
- approvedPriority reviewDec 20, 2024
Chemistry & pharmacology
Loading structure…
SMILES
[2H]C([2H])([2H])C(c1cc(C(C)(C)C)c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)(C([2H])([2H])[2H])C([2H])([2H])[2H]- Mol. weight
- 401.55 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297603 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06299696 | Phase 1 | Mar 26, 2024 | Vertex |
| NCT06299709 | Phase 1 | Mar 13, 2024 | Vertex |
| NCT05844449 | Phase 3 | Aug 11, 2023 | Vertex |
| NCT05444257 | Phase 3 | Nov 8, 2022 | Vertex |
| NCT05535959 | Phase 1 | Sep 15, 2022 | Vertex |
| NCT05437120 | Phase 1 | Jul 22, 2022 | Vertex |
| NCT05422222 | Phase 3 | Jun 21, 2022 | Vertex |
| NCT05076149 | Phase 3 | Oct 27, 2021 | Vertex |
| NCT05033080 | Phase 3 | Sep 14, 2021 | Vertex |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vertex | For profit | 9 | 9 | 2 | 2021 |
1 organizations
Page 1 / 1